137 related articles for article (PubMed ID: 22659964)
1. Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation.
Tsai CM; Chiu CH; Chang KT; Chen JT; Lai CL; Chen YM; Hsiao SY
J Thorac Oncol; 2012 Aug; 7(8):1218-27. PubMed ID: 22659964
[TBL] [Abstract][Full Text] [Related]
2. Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed?
Tsai CM; Chen JT; Stewart DJ; Chiu CH; Lai CL; Hsiao SY; Chen YM; Chang KT
J Thorac Oncol; 2011 Mar; 6(3):559-68. PubMed ID: 21258258
[TBL] [Abstract][Full Text] [Related]
3. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
6. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
Okabe T; Okamoto I; Tsukioka S; Uchida J; Hatashita E; Yamada Y; Yoshida T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
Clin Cancer Res; 2009 Feb; 15(3):907-13. PubMed ID: 19188161
[TBL] [Abstract][Full Text] [Related]
7. In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines.
Cheng H; An SJ; Zhang XC; Dong S; Zhang YF; Chen ZH; Chen HJ; Guo AL; Lin QX; Wu YL
Cancer Chemother Pharmacol; 2011 Mar; 67(3):637-46. PubMed ID: 20495920
[TBL] [Abstract][Full Text] [Related]
8. Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.
Li XY; Wu JZ; Cao HX; Ma R; Wu JQ; Zhong YJ; Feng JF
Oncol Rep; 2013 May; 29(5):1975-82. PubMed ID: 23440266
[TBL] [Abstract][Full Text] [Related]
9. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
Suda K; Tomizawa K; Fujii M; Murakami H; Osada H; Maehara Y; Yatabe Y; Sekido Y; Mitsudomi T
J Thorac Oncol; 2011 Jul; 6(7):1152-61. PubMed ID: 21597390
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.
Kitazaki T; Oka M; Nakamura Y; Tsurutani J; Doi S; Yasunaga M; Takemura M; Yabuuchi H; Soda H; Kohno S
Lung Cancer; 2005 Sep; 49(3):337-43. PubMed ID: 15955594
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
Mukohara T; Engelman JA; Hanna NH; Yeap BY; Kobayashi S; Lindeman N; Halmos B; Pearlberg J; Tsuchihashi Z; Cantley LC; Tenen DG; Johnson BE; Jänne PA
J Natl Cancer Inst; 2005 Aug; 97(16):1185-94. PubMed ID: 16106023
[TBL] [Abstract][Full Text] [Related]
12. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
[TBL] [Abstract][Full Text] [Related]
13. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S
Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
[TBL] [Abstract][Full Text] [Related]
15. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.
Yamamoto C; Basaki Y; Kawahara A; Nakashima K; Kage M; Izumi H; Kohno K; Uramoto H; Yasumoto K; Kuwano M; Ono M
Cancer Res; 2010 Nov; 70(21):8715-25. PubMed ID: 20959484
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
Tracy S; Mukohara T; Hansen M; Meyerson M; Johnson BE; Jänne PA
Cancer Res; 2004 Oct; 64(20):7241-4. PubMed ID: 15492241
[TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.
Choi YJ; Rho JK; Jeon BS; Choi SJ; Park SC; Lee SS; Kim HR; Kim CH; Lee JC
Cancer Chemother Pharmacol; 2010 Jul; 66(2):381-8. PubMed ID: 19921194
[TBL] [Abstract][Full Text] [Related]
18. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
Xie M; He CS; Wei SH; Zhang L
Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells.
Serizawa M; Takahashi T; Yamamoto N; Koh Y
J Thorac Oncol; 2013 Mar; 8(3):259-69. PubMed ID: 23334091
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
Morgillo F; Sasso FC; Della Corte CM; Vitagliano D; D'Aiuto E; Troiani T; Martinelli E; De Vita F; Orditura M; De Palma R; Ciardiello F
Clin Cancer Res; 2013 Jul; 19(13):3508-19. PubMed ID: 23695170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]